Elo Mutual Pension Insurance Co Grows Position in Bristol Myers Squibb Company $BMY

Elo Mutual Pension Insurance Co boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 23.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 302,104 shares of the biopharmaceutical company’s stock after buying an additional 57,692 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Bristol Myers Squibb were worth $13,625,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after buying an additional 1,058,803 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC lifted its stake in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after purchasing an additional 723,459 shares in the last quarter. Norges Bank bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,554,154,000. Finally, Ameriprise Financial Inc. grew its position in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after purchasing an additional 432,158 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — the readout validates an ADC Bristol Myers licensed and could materially boost future revenue potential (deal carries >$8B long‑term economics that BMS has highlighted), which is likely the main driver lifting sentiment today. Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
• Neutral Sentiment: Coverage pieces note BMY has lagged the Nasdaq over the last year, but Wall Street remains moderately optimistic — this frames today’s rally as driven more by idiosyncratic clinical news than by broad market leadership. Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
• Neutral Sentiment: Sector updates and analyst writeups (momentum/value profiles) are highlighting BMY as a top‑ranked momentum/value/dividend candidate for different investor styles — these stories can attract additional retail and income‑oriented flows but are not major catalysts by themselves. Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: General pharma‑sector coverage and updates mention BMY among large‑cap players with deep late‑stage pipelines — supportive context but not a standalone catalyst. Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target (implying slight downside versus recent levels); that cautious initiation caps upside for some investors and may limit the size of gains if broader sentiment cools. RBC Capital Initiates Bristol Myers (BMY) with $60 Target

Bristol Myers Squibb Stock Up 1.9%

Shares of Bristol Myers Squibb stock opened at $62.23 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a market cap of $126.74 billion, a P/E ratio of 18.04, a PEG ratio of 0.18 and a beta of 0.26. The firm’s 50 day moving average price is $56.98 and its 200-day moving average price is $50.57. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the company earned $1.67 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research reports. Leerink Partners increased their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Citigroup boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. HSBC reissued a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.